

AUM

September 30, 2026

₹3,501.37Cr.

Investment Objective

To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.

Investment Strategy

- Domestic healthcare spends to increase due to rising longevity, low penetration and growing elderly population
- Rising chronic diseases to result in repeated buying and higher margins for pharma companies
- Growing share of Indian companies in US generics, improved pricing erosion environment and large chunk of drugs going off-patent over the next few years provides a big opportunity for Indian pharma companies
- Biosimilars - an untapped long-term growth lever for Indian pharma companies
- Indian pharma companies are now playing pivotal role in driving global innovation through the CDMO* route
- Manufacturing Leadership - India has the second highest share of USFDA approved facilities; the manufacturing competitiveness has improved further with introduction of PLI scheme and low labour cost.

*CDMO - Contract Development and Manufacturing Organization. Source: USFDA - United States Food and Drug Administration

Top 10 Equity Holdings (as on September 30, 2026)

Company	Industry*	% to NAV
Divis Laboratories Ltd.	Pharmaceuticals & Biotechnology	9.39
Sun Pharmaceutical Industries Ltd.	Pharmaceuticals & Biotechnology	8.28
Alkem Laboratories Ltd.	Pharmaceuticals & Biotechnology	4.64
Cipla Ltd.	Pharmaceuticals & Biotechnology	4.15
Apollo Hospitals Enterprise Ltd.	Healthcare Services	3.69
Torrent Pharmaceuticals Ltd.	Pharmaceuticals & Biotechnology	3.65
Max Healthcare Institute Limited	Healthcare Services	3.61
Aster DM Quality Care Limited	Healthcare Services	3.56
Lupin Ltd.	Pharmaceuticals & Biotechnology	3.55
Neuland Laboratories Limited	Pharmaceuticals & Biotechnology	3.24

* Industry classification as recommended by AMFI. For complete portfolio details please refer to the website www.hdfcfund.com

Quantitative Data (Risk Ratios)

Standard Deviation	16.286%
Beta	0.944
Sharpe Ratio*	1.383

Computed for the 3-yr period ended September 30, 2026 Based on month-end NAV.* Risk free rate: 5.28% (Source: FIMMDA MIBOR) For schemes which have not completed 3 years, data is computed since inception.

Portfolio Turnover Ratio

Equity Turnover	35.64%
Total Turnover	35.64%
Total Turnover = Equity + Debt + Derivative	

Market Cap Segment-wise Exposure

	Apr 2026	May 2026	Jun 2026	Jul 2026	Aug 2026	Sep 2026
Large	28.9%	27.4%	28.9%	27.3%	27.9%	29.2%
Mid	34.5%	34.2%	29.3%	37.3%	33.2%	30.1%
Small	33.9%	37.0%	39.1%	34.9%	37.4%	37.5%

% of Net Assets (As per AMFI classification as on June 2026)

Fund Facts

Category of Scheme	SECTORAL FUND
Fund Manager*	Nikhil Mathur (since October 4, 2023), Bhagyesh Kagalkar (Gold/Silver Instruments) (since August 26, 2026)
Inception Date	October 4, 2023
Benchmark	BSE Healthcare Index (TRI)
Investment Plans / Options	Regular Plan, Direct Plan. Under Each Plan: Growth & IDCW Option. The IDCW Option offers following Sub-Options: Payout of IDCW Option; and Reinvestment of IDCW Option.
\$\$ Exit Load	<ul style="list-style-type: none"> • In respect of each purchase/switch-in of units, an Exit load of 1% is payable if units are redeemed/switched-out within 30 days from the date of allotment. • No Exit Load is payable if units are redeemed / switched-out after 30 days from the date of allotment.

*Dedicated fund manager for overseas investments: Mr. Gopal Agrawal (since September 01, 2026)

What's In What's Out (31st August 2026 vs 30th September 2026)


Entry	
Company Name	Industry
Entero Healthcare Solutions Limited	Retailing

Increased Exposure	
Company Name	Industry
Alkem Laboratories Ltd.	Pharmaceuticals & Biotechnology
Apollo Hospitals Enterprise Ltd.	Healthcare Services
Aster DM Quality Care Limited	Healthcare Services
Cipla Ltd.	Pharmaceuticals & Biotechnology
Divis Laboratories Ltd.	Pharmaceuticals & Biotechnology
Dr Reddys Laboratories Ltd.	Pharmaceuticals & Biotechnology
Gland Pharma Ltd.	Pharmaceuticals & Biotechnology
Max Healthcare Institute Limited	Healthcare Services
Global Health Limited	Healthcare Services
Rubicon Research Limited	Pharmaceuticals & Biotechnology
Sun Pharmaceutical Industries Ltd.	Pharmaceuticals & Biotechnology
Jupiter Life Line Hospitals Limited	Healthcare Services

Exit	
Company Name	Industry
Ajanta Pharma Limited	Pharmaceuticals & Biotechnology
Fortis Healthcare Limited	Healthcare Services

Decreased Exposure	
Company Name	Industry
Nil	Nil

Product labelling and Riskometer

This product is suitable for investors who are seeking*	Riskometer#
<ul style="list-style-type: none"> To generate long-term capital appreciation Investment predominantly in equity & equity related instruments of Pharma and healthcare companies. 	 <p>The risk of the scheme is very high</p>
*Investors should consult their financial advisers, if in doubt about whether the product is suitable for them	

For latest Riskometer, investors may refer to the Monthly Portfolios disclosed on the website of the Fund viz. www.hdfcfund.com
Scheme riskometer as of September 30, 2026

The Scheme being sectoral in nature carries higher risks versus diversified equity mutual funds on account of concentration and sector specific risks.

Stocks/Sectors/Themes referred should not be construed as an investment advice or a recommendation by HDFC Mutual Fund ("the Fund") / HDFC AMC to buy or sell the stock or any other security covered under the respective sector/stocks/themes. The Fund may or may not have any present or future positions in these stocks/sectors/themes.

\$\$ Exit Load: (i) No Exit Load shall be levied for switching between Plans / Options within the Scheme. However, exit load will be applicable if the units are switched-out / redeemed from the Scheme within the exit load period from the initial date of purchase. (ii) No Exit load will be levied on bonus Units and on units allotted on Re-investment of Income Distribution cum Capital Withdrawal. (iii) No Exit load will be levied on Units allotted in the Target Scheme under the Transfer of Income Distribution cum Capital Withdrawal (IDCW) Plan Facility (TIP Facility). (iv) In case of Systematic Transactions such as Systematic Investment Plan (SIP), Flex Systematic Investment Plan (Flex SIP), Systematic Transfer Plan (STP), HDFC Flex Systematic Transfer Plan (Flex STP), HDFC Swing Systematic Transfer Plan (Swing STP), HDFC Flexindex Plan (Flexindex) etc., Exit Load, if any, prevailing on the date of registration / enrolment shall be levied.